Navigation Links
Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
Date:1/30/2008

SAN CARLOS, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it has enrolled the first patient in a single-center, Phase 1 trial to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172, a thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers.

"This proof-of-concept trial will allow us to quickly determine NU172's potential to achieve rapid onset and offset of anticoagulation," said Michael Levy, executive vice president of research and development for Nuvelo. "We look forward to sharing top-line data from this trial in the first half of 2008."

NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions. Data from early animal models suggest that NU172 has the potential for predictable anticoagulant effects, rapid onset and offset of action, and avoidance of heparin-induced thrombocytopenia.

About Aptamers

Aptamers are chemically synthesized single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Characteristics of aptamers include high specificity and affinity, and the ability to target protein-protein interactions.

About Nuvelo and Archemix's Joint Collaborative Effort

In August 2006, Nuvelo expanded its collaboration with Archemix to develop and commercialize aptamers that have a sho
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
2. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
3. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
4. Northwestern Memorial Transplant Program Initiates New Study
5. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
6. SGX Initiates Phase I Trials for SGX523
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
9. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
10. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
11. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... - Bentley,Pharmaceuticals, Inc. (NYSE: BNT), a specialty ... abstract sponsored by,the Company has been accepted ... Association 67th Scientific Sessions in Chicago.,The abstract, ... Comparison Study of Intranasal Insulin Spray,(Nasulin(TM)) and ...
... Among Patients with,Active Disease, MOUNTAIN VIEW, ... Inc., a clinical-stage biopharmaceutical company,focused on ... target the chemokine system,presented data today ... trial of,Traficet-EN (CCX282-B), an orally-active anti-inflammatory ...
Cached Medicine Technology:Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 2ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 4ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 5
(Date:7/10/2014)... The Capital Institute for Neurosciences at Capital Health ... a clinical trial that delivers chemotherapy to brain tumors ... the procedure, done at Capital Health Medical Center – ... tiny catheter through the patient’s femoral artery in the ... the brain. Once the catheter reached the brain, chemotherapy ...
(Date:7/10/2014)... Colorado (PRWEB) July 10, 2014 ... will gather in Copenhagen this July 13-17 to ... bringing the world closer to breakthroughs in dementia ... the world’s largest conference of its kind. , ... AAIC serves as a catalyst for generating new ...
(Date:7/10/2014)... 10, 2014 In his latest blog ... drug treatment facility CEO Per Wickstrom has listed 5 ... trying to confirm an appointment, get information or sometimes ... following-up without being annoying is a skill that most ... a way to keep the dialogue moving without coming ...
(Date:7/10/2014)... (July 8, 2014) A new study from Colorado ... improvements, poor oral health remains a major problem in ... "The oral health among Native Americans is abysmal with ... of the country," said Terrence Batliner, DDS, MBA, associate ... at the School of Public Health. "The number one ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Teens who ... are more likely to develop emotional symptoms such as ... factors such as these that may exacerbate issues teens ... appropriate treatment and in making decisions about when to ... school for these athletes," study authors Lisa Koehl and ...
Breaking Medicine News(10 mins):Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Some Teens May Face Emotional Problems After Concussion 2
... 26 Velos, Inc., the recognized leader and ... and Net.Orange, Inc., the respected healthcare Internet solutions ... Cancer Research Centers (Mary Crowley). The two companies ... for strong central clinical research infrastructure and implementation ...
... Sandals(R) Originals2 Footwear by BeechHUNTINGTON BEACH, Calif., Feb. ... Yoga Sandals(R) Originals line with new adjustable ... This patented foot therapy can now be customized ... foot , increasing flexibility and helping improve balance ...
... LLC ( http://www.GlenwoodSystems.com ) launches the GlaceComplete product suite which seamlessly ... an assisted medical billing process. The product has been designed ... maximizing revenue contribution for the average office based medical practice. ... ...
... Today, AmeriGlide announced the recipient of this years AmeriGlide Achiever Scholarship. ... a wheelchair. , ... Raleigh, NC (PRWEB) February 26, ... of the first semi-annual AmeriGlide Achiever Scholarship. The AmeriGlide Achiever Scholarship ...
... Honored for Comebacks from Ostomy SurgeryWASHINGTON, Feb. 25 ... improving the lives of other ostomates, was named this ... pilot Robert (Bob) Cuyler was named the first recipient ... ceremony here this evening. Founded in 1984 by ...
... ArvinMeritor (NYSE: ARM ) today announced that ... by Lin Cummins, senior vice president of Communications for ArvinMeritor, ... one of the most challenging economic times in history, I ... and individuals to help wipe out heart disease, the number ...
Cached Medicine News:Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 2Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 3Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 4Health News:Sandal Evolution(R) Takes a Healthy Step 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 3Health News:AmeriGlide Announces Recipient of AmeriGlide Achiever Scholarship 2Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 2Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 3Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 4Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 5Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 6Health News:ArvinMeritor Proud to Sponsor American Heart Association Campaign 2
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
Medicine Products: